cytellin and Coronary-Disease

cytellin has been researched along with Coronary-Disease* in 26 studies

Reviews

3 review(s) available for cytellin and Coronary-Disease

ArticleYear
Nutritional recommendations for preventing coronary heart disease in women: evidence concerning whole foods and supplements.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2010, Volume: 20, Issue:6

    Some food groups and supplements have been recommended for preventing coronary heart disease (CHD) in women. In this article, evidence on recommendations for some of these food groups (whole grains, fruits, vegetables, fish, nuts, and soy) and supplements (phytosterols, antioxidants, folic acid, and B-complex vitamins) is reviewed. Additionally, gender differences in nutritional requirements and recommendations are described.. Studies of nutrition in women and those emphasizing gender differences in nutritional requirements were selected for this review.. Observational data support the benefit of vegetables, fruits, and whole grains in CHD prevention. Trial data provide support for consuming fish at least twice a week, although women of childbearing age should limit their intake of fish that may contain high levels of mercury. Nuts are nutritious snacks but their caloric impact must be considered. Soy products do not affect low-density lipoprotein cholesterol (LDL-C) or CHD but may be beneficial in replacing high-fat meat. Foods supplemented with plant stanol/sterol-esters are recommended for reducing LDL-C. Antioxidant supplementation is not recommended for prevention of heart disease. A direct causal relationship between vitamin D deficiency and CHD has not been established. Homocysteine lowering through folic acid and B-complex vitamin supplementation has not been proven to improve CHD risk. More gender-specific analyses are needed to determine whether nutritional requirements differ between men and women.

    Topics: Adult; Aged; Coronary Disease; Diet; Diet, Fat-Restricted; Diet, Mediterranean; Dietary Supplements; Fat Substitutes; Female; Humans; Hyperlipoproteinemias; Male; Middle Aged; Nutritional Status; Risk Factors; Sex Factors; Sitosterols; Women's Health

2010
Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol.
    Pharmacotherapy, 2005, Volume: 25, Issue:2

    To compare the efficacy and safety of plant sterols and stanols as well as policosanol in the treatment of coronary heart disease, as measured by a reduction in low-density lipoprotein cholesterol (LDL) levels.. Systematic review and meta-analysis of randomized controlled trials.. A total of 4596 patients from 52 eligible studies.. We searched MEDLINE, EMBASE, the Web of Science, and the Cochrane Library from January 1967-June 2003 to identify pertinent studies. Reduction of LDL levels was the primary end point; effects on other lipid parameters and withdrawal of study patients due to adverse effects were the secondary end points. Weighted estimates of percent change in LDL were -11.0% for plant sterol and stanol esters 3.4 g/day (range 2-9 g/day [893 patients]) versus -2.3% for placebo (769 patients) in 23 eligible studies, compared with -23.7% for policosanol 12 mg/day (range 5-40 mg/day [1528 patients]) versus -0.11% for placebo (1406 patients) in 29 eligible studies. Cumulative p values were significantly different from placebo for both (p<0.0001). The net LDL reduction in the treatment groups minus that in the placebo groups was greater with policosanol than plant sterols and stanols (-24% versus -10%, p<0.0001). Policosanol also affected total cholesterol, high-density lipoprotein cholesterol (HDL), and triglyceride levels more favorably than plant sterols and stanols. Policosanol caused a clinically significant decrease in the LDL:HDL ratio. Pooled withdrawal rate due to adverse effects and combined relative risk for patients who withdrew were 0% and 0.84, respectively (95% confidence interval [CI] 0.36-1.95, p=0.69), for plant sterols and stanols across 20 studies versus 0.86% and 0.31, respectively (95% CI 0.20-0.48, p<0.0001), for policosanol across 28 studies.. Plant sterols and stanols and policosanol are well tolerated and safe; however, policosanol is more effective than plant sterols and stanols for LDL level reduction and more favorably alters the lipid profile, approaching antilipemic drug efficacy.

    Topics: Anticholesteremic Agents; Coronary Disease; Fatty Alcohols; Humans; Hyperlipidemias; Phytosterols; Randomized Controlled Trials as Topic; Sitosterols

2005
[When statins alone are insufficient for lowering lipid levels. Efficacy and risks of lipid lowering combination therapies, in particular, that of statin-fibrate combination].
    Der Internist, 1999, Volume: 40, Issue:12

    Topics: Coronary Disease; Drug Therapy, Combination; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Niacin; Sitosterols

1999

Trials

4 trial(s) available for cytellin and Coronary-Disease

ArticleYear
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Atherosclerosis, 2014, Volume: 232, Issue:1

    Combination therapy may help high-risk patients achieve low-density lipoprotein cholesterol (LDL-C) goals. Impact of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg (RSV10/EZE10 and RSV20/EZE10) has not been fully characterized previously. GRAVITY (NCT00525824) compared efficacy, safety and effect on biomarkers of RSV10/EZE10 and RSV20/EZE10 vs. simvastatin 40 mg and 80 mg plus EZE10 (SIM40/EZE10 and SIM80/EZE10) in patients with coronary heart disease (CHD) or CHD risk equivalent.. Adult patients (n = 833) were randomized to RSV10/EZE10, RSV20/EZE10, SIM40/EZE10 or SIM80/EZE10. Following a 6-week dietary lead-in, patients received 6 weeks' statin monotherapy followed by same statin dose plus ezetimibe for 6 more weeks. Primary endpoint was LDL-C change from baseline to 12 weeks.. Significantly greater (p < 0.05) reductions in LDL-C and other atherogenic lipids were observed with RSV20/EZE10 vs. SIM40/EZE10 and SIM80/EZE10 and with RSV10/EZE10 vs. SIM40/EZE10. A significantly greater proportion of patients achieved LDL-C goals of <100 mg/dl and <70 mg/dl with RSV20/EZE10 vs. SIM40/EZE10 and SIM80/EZE10 and with RSV10/EZE10 vs. SIM40/EZE10. LDL-C was reduced ∼10-14% further with combination therapy vs. monotherapy. Statin monotherapy reduced cholesterol and bile acid synthesis biomarkers, ezetimibe reduced β-sitosterol (sterol absorption marker), and combination therapy achieved additive reductions in lipoprotein-associated phospholipase A2 mass and activity, free cholesterol and 7-ketocholesterol. Safety profiles of rosuvastatin/ezetimibe and simvastatin/ezetimibe combinations were comparable.. Co-administration of rosuvastatin 10 or 20 mg plus ezetimibe achieved significant improvements in lipid profiles in high-risk patients vs. simvastatin 40 or 80 mg plus ezetimibe.

    Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome

2014
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial.
    Journal of lipid research, 2010, Volume: 51, Issue:1

    Cholesterol homeostasis, defined as the balance between absorption and synthesis, influences circulating cholesterol concentrations and subsequent coronary heart disease (CHD) risk. Statin therapy targets the rate-limiting enzyme in cholesterol biosynthesis and is efficacious in lowering CHD events and mortality. Nonetheless, CHD events still occur in some treated patients. To address differences in outcome during pravastatin therapy (40 mg/day), plasma markers of cholesterol synthesis (desmosterol, lathosterol) and fractional cholesterol absorption (campesterol, sitosterol) were measured, baseline and on treatment, in the Prospective Study of Pravastatin in the Elderly at Risk trial participants with (cases, n = 223) and without (controls, n = 257) a CHD event. Pravastatin therapy decreased plasma LDL-cholesterol and triglycerides and increased HDL-cholesterol concentrations to a similar extent in cases and controls. Decreased concentrations of the cholesterol synthesis markers desmosterol (-12% and -11%) and lathosterol (-50% and -56%) and increased concentrations of the cholesterol absorption markers campesterol (48% and 51%) and sitosterol (25% and 26%) were observed on treatment, but the magnitude of change was similar between cases and controls. These data suggest that decreases in cholesterol synthesis in response to pravastatin treatment were accompanied by modest compensatory increases in fractional cholesterol absorption. The magnitude of these alterations were similar between cases and controls and do not explain differences in outcomes with pravastatin treatment.

    Topics: Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Desmosterol; Female; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phytosterols; Pravastatin; Sitosterols; Triglycerides

2010
Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.
    The Journal of laboratory and clinical medicine, 2003, Volume: 141, Issue:2

    We studied changes in serum cholestanol and plant sterols (indexes of cholesterol absorption) and cholesterol precursors (indexes of cholesterol synthesis) in response to cholesterol reduction by way of 1 year's treatment with atorvastatin (n = 102) and simvastatin (n = 105) treatments in patients with coronary heart disease. Serum cholesterol levels and ratios of the precursor sterols to cholesterol after 1 year of treatment were reduced in proportion to the pretreatment values (33% +/- 1% by simvastatin and 36% +/- 1% by atorvastatin; P <.01 for difference between groups) for cholesterol; the respective reductions in the precursor sterol:cholesterol ratios were also higher with atorvastatin (50% +/- 2% for lathosterol) than with simvastatin (42% +/- 1%; P <.01 between groups), but the ratio of squalene to cholesterol was increased (17% +/- 5%, P <.001) by atorvastatin. Plant sterol concentrations were gradually increased by atorvastatin but decreased initially by simvastatin. However, their ratios with respect to cholesterol were increased by as much as 82% with atorvastatin and by as much as 39% with simvastatin. In conclusion, effective inhibition of cholesterol synthesis and subsequent reduction in serum cholesterol levels by statins lead to increases in serum plant-sterol levels, probably as a result of reduced biliary secretion and enhanced absorption of these sterols. Because serum plant sterols have been claimed to be involved in the early development of atherosclerosis, the question arises whether continuously increasing serum plant sterols during long-term statin treatment should be prevented by cholesterol malabsorption (eg, by plant stanol ester consumption), especially in subjects with high baseline plant sterol values and effective sterol absorption.

    Topics: Anticholesteremic Agents; Atorvastatin; Cholestanol; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols; Squalene; Sterols

2003
Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol.
    Arteriosclerosis, thrombosis, and vascular biology, 2000, Volume: 20, Issue:5

    Coronary patients with low baseline ratios of serum cholestanol and plant sterols to cholesterol (indicating low cholesterol absorption) but not those with high ratios (high absorption) experienced reduced recurrences of coronary events during simvastatin treatment in the Scandinavian Simvastatin Survival Study. Thus, in the present study, serum cholesterol, its precursor sterols (reflecting cholesterol synthesis), plant sterols (campesterol and sitosterol), and cholestanol were measured before and during a 5-year period of placebo treatment (n=433) and simvastatin treatment (n=434) in patients from a subgroup of the Scandinavian Simvastatin Survival Study to determine whether changes in cholesterol synthesis and serum levels were related to cholesterol absorption. Serum cholesterol level was unchanged, the ratios of cholesterol precursor sterols to cholesterol were decreased, and the ratios of plant sterols to cholesterol were increased in relation to increasing baseline ratios of cholestanol quartiles. The latter predicted 5-year ratios and simvastatin-induced reductions of the precursor sterols, with the lowering of the ratios (cholesterol synthesis reduction) being almost twice higher in the lowest versus the highest quartile. The ratios of plant sterols, especially campesterol, to cholesterol were markedly increased during simvastatin treatment, mostly in subjects with the highest baseline cholestanol quartiles. Simvastatin reduced serum cholesterol more (P=0.003) in the lowest versus the highest cholestanol quartile during the 5-year treatment period. The results show for the first time that baseline cholesterol metabolism, measured by serum noncholesterol sterols, predicts the effectiveness of simvastatin in reducing cholesterol synthesis and serum levels of cholesterol. The drug suppresses the synthesis of cholesterol markedly more effectively in subjects with high than with low baseline synthesis but reduces respective serum cholesterol levels less markedly than synthesis. Subjects with high cholesterol absorption and low synthesis may need a combination therapy to lower more effectively their serum cholesterol levels and prevent an increase in the levels of plant sterols.

    Topics: Anticholesteremic Agents; Body Weight; Cholestanol; Cholesterol; Coronary Disease; Desmosterol; Humans; Phytosterols; Placebos; Simvastatin; Sitosterols; Sterols

2000

Other Studies

19 other study(ies) available for cytellin and Coronary-Disease

ArticleYear
Relation of non-cholesterol sterols to coronary risk factors and carotid intima-media thickness: the Cardiovascular Risk in Young Finns Study.
    Atherosclerosis, 2010, Volume: 209, Issue:2

    The aim of the present study was to evaluate the role of cholesterol metabolism in the development of atheromatous artery disease.. Serum synthesis (cholesterol precursors) and absorption markers (cholestanol, campesterol, sitosterol, and avenasterol) were related to coronary risk factors and vascular structure in a population-based sample of 468 randomly selected 33-39-year-old men on their regular habitual diet. Carotid artery intima-media thickness (IMT) and serum lipids (including cholesterol) and sterols were measured in 2001, and the subjects were ranked to decreasing cholesterol synthesis depicted by serum cholestanol quartiles defined 21 years earlier in adolescence.. Serum cholesterol was correlated with absorption (e.g. serum campesterol, p<0.05), but not with synthesis, or with cholestanol quartiles. Cholesterol metabolism (synthesis/absorption markers) decreased linearly (about 50%) with the increasing cholestanol quartiles. IMT differed between the age groups, but not between cholestanol quartiles. Serum triglycerides, apoprotein B, and body mass index decreased, and non-HDL cholesterol/apoprotein B values increased between the cholestanol quartiles, whereas LDL cholesterol was unchanged. Cholesterol synthesis markers were related to blood pressure and serum triglycerides, and negatively to HDL cholesterol level in total population and in most of the cholestanol quartiles (p from 0.05 to 0.001).. Variables of metabolic syndrome accumulated in quartiles of high synthesis of cholesterol. Non-cholesterol sterols were related to many classic coronary risk factors, but virtually not to serum cholesterol or vascular structure.

    Topics: Adolescent; Adult; Carotid Arteries; Child; Cholestanol; Cholesterol; Coronary Disease; Follow-Up Studies; Humans; Male; Phytosterols; Risk Factors; Sitosterols; Sterols; Tunica Intima; Tunica Media; Ultrasonography

2010
The effects of statins and sitosterols: benefit or not?
    Current atherosclerosis reports, 2009, Volume: 11, Issue:1

    Statins reduce plasma plant sterol concentrations and, less consistently, their ratios to cholesterol in short-term studies. They most likely accomplish this by decreasing their transport protein levels. In long-term treatment with large doses of effective statins, serum plant sterol concentrations and frequently their ratios to cholesterol are consistently increased, especially with high, as opposed to low, baseline ratios. Enhanced intestinal absorption, decreased biliary secretion, and reversed cholesterol and plant sterol transport could explain these findings. However, statin treatment increases plant sterol ratios in serum and also in arterial plaques of endarterectomized patients. No trials of functional foods with plant sterols or stanols are available for coronary heart disease, even though their combination with statins effectively reduces low-density lipoprotein cholesterol. Plant sterols increase and plant stanols decrease serum plant sterols. Long-term statin treatment lowers coronary heart disease events only in patients with low baseline plant sterols who have high cholesterol synthesis. No convincing evidence is available that statin-induced phytosterolemia worsens atherosclerosis.

    Topics: Cholesterol; Coronary Disease; Diet; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phytosterols; Sitosterols

2009
Moderately elevated plant sterol levels are associated with reduced cardiovascular risk--the LASA study.
    Atherosclerosis, 2008, Volume: 196, Issue:1

    Functional foods with supplementation of plant sterols are already used by millions of people. However, at the same time it is current scientific thinking that elevation of plant sterols in the circulation causes coronary heart disease. Therefore, this study aimed to define the risk for coronary heart disease associated with moderately high plant sterol plasma levels in a cohort of elderly. In this study, we evaluated the association between plant sterols and coronary heart disease in a cohort of 1242 subjects older than 65 years, participating at the Longitudinal Aging Study Amsterdam (LASA). Concentrations of sitosterol, campesterol, brassicasterol and stigmasterol were assessed using highly sensitive and specific gas chromatography-mass spectrometry-selected ion-monitoring. Plant sterol concentrations (and their ratios to cholesterol) were slightly, however, significantly lower in patients with coronary heart disease. Moreover, high plasma concentrations of a marker plant sterol, sitosterol, were associated with a markedly reduced risk for coronary heart disease (OR 0.78, CI 0.62-0.98, p<0.05). In contrast neither plant stanols (sitostanol or campestanol) nor the cholesterol synthesis markers (lathosterol, lanosterol and desmosterol) nor their ratios to cholesterol were significantly different in the study groups. These data suggest that plant sterols could have neutral or even protective effects on development of coronary heart disease, which have to be confirmed in interventional trials.

    Topics: Aged; Aged, 80 and over; Cholesterol; Coronary Disease; Cross-Sectional Studies; Female; Humans; Logistic Models; Male; Peripheral Vascular Diseases; Phytosterols; Risk Factors; Sitosterols

2008
Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2007, Volume: 14, Issue:2

    Plant stanol esters in spreads have demonstrated efficacy in reducing serum cholesterol. The cost-effectiveness of plant stanol esters in the prevention of coronary heart disease, however, has remained unevaluated.. A Bayesian modelling approach was applied to synthesize clinical evidence and evaluate the cost-effectiveness (Euro/quality-adjusted life years) of plant stanol esters in spread in the prevention of coronary heart disease based on published FINRISK and 4S risk functions.. The regular use of plant stanol esters reduced total serum cholesterol by -0.362 mmol/l [95% credibility interval (CrI) -0.31 to -0.41]. The corresponding placebo-adjusted reduction attributable to stanol esters when combined with statin was -0.385 mmol/l (95% CrI -0.18 to -0.61). The cost-effectiveness estimations were assessed for men and women separately at four different initial ages at which the regular use of stanol esters was assumed to be started. The base case cost per quality-adjusted life years gained by using stanol esters regularly ranged from 7436 to 20,999 Euro in men and from 34,327 to 112,151 Euro in women based on the initial starting age. According to uncertainty analysis, there is over a 90% probability that the use of plant stanol esters is cost-effective for men inclusively and for 60-year-old and older women assuming that decision-makers' maximum willingness to pay per quality-adjusted life year is 50,000 Euro.. A recommendation that plant stanol ester-containing spreads be used as a part of daily diet replacing regular spread could be viewed as potentially cost-effective public health policy in the prevention of CHD in all adult men and in older age-groups of women with total serum cholesterol levels of 5 mmol/l or greater.

    Topics: Adult; Aged; Bayes Theorem; Biomarkers; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Female; Finland; Humans; Male; Markov Chains; Middle Aged; Phytotherapy; Plant Preparations; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Sitosterols; Treatment Outcome; Uncertainty

2007
Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) study.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:1

    Sitosterolemia, a rare genetic disorder characterized by profoundly elevated plasma sitosterol concentrations, is associated with premature atherosclerosis in some individuals. This study was conducted to evaluate if the modest sitosterol elevations seen in the general population are also associated with the occurrence of coronary events.. A nested case-control study using stored samples from male participants in the Prospective Cardiovascular Münster (PROCAM) study was performed. Each of 159 men who suffered a myocardial infarction or sudden coronary death (major coronary event) within 10 years of follow-up in PROCAM was matched with 2 controls (N = 318) by age, smoking status, and date of investigation. Analysis was performed using conditional logistic regression. Plasma sitosterol concentrations were elevated in cases compared with controls (4.94 +/- 3.44 micromol/L versus 4.27 +/- 2.38 micromol/L; P = 0.028). The upper quartile of sitosterol (>5.25 micromol/L) was associated with a 1.8-fold increase in risk (P < 0.05) compared with the lower three quartiles. Among men with an absolute coronary risk > or = 20% in 10 years as calculated using the PROCAM algorithm, high sitosterol concentrations were associated with an additional 3-fold increase in the incidence of coronary events (P = 0.032); a similar, significant relationship was observed between a high sitosterol/cholesterol ratio and coronary risk (P = 0.030).. Elevations in sitosterol concentrations and the sitosterol/cholesterol ratio appear to be associated with an increased occurrence of major coronary events in men at high global risk of coronary heart disease. Further evaluations are warranted to confirm these preliminary findings.

    Topics: Adolescent; Adult; Aged; Case-Control Studies; Cholesterol; Cohort Studies; Coronary Disease; Germany; Humans; Incidence; Logistic Models; Male; Middle Aged; Prospective Studies; Risk Factors; Sitosterols; Smoking

2006
Serum plant sterols as a potential risk factor for coronary heart disease.
    Metabolism: clinical and experimental, 2002, Volume: 51, Issue:12

    In patients with the inherited disease of phytosterolemia, elevated concentrations of plant sterols (eg, campesterol and sitosterol) have been implicated as a risk factor for premature atherosclerosis. Whether plasma concentrations of campesterol and sitosterol are risk factors for coronary heart disease (CHD) in nonphytosterolemia subjects has not been established. Therefore, the present study examined the role of plant sterols in patients admitted for elective artery coronary bypass graft (ACBG). Serum concentrations of campesterol and sitosterol, as well as lathosterol, desmosterol, cholestanol, and lipoproteins were analyzed in 42 men and 11 women without lipid-lowering treatment during the past. Twenty-six patients reported a positive family history in their first-degree relatives for CHD. Lipid profile and other risk factors were comparable in both groups. Patients with a positive family history for CHD had significant higher plasma levels of campesterol (.50 +/-.17 v.38 +/-.16 mg/dL; P =.011), sitosterol (.40 +/-.11 v.31 +/-.11 mg/dL; P =.004) and their ratios to cholesterol. Lathosterol, desmosterol, cholestanol, and their ratios to cholesterol were not significantly different. Analysis of covariance (ANCOVA) analysis showed no influence of sex, age, triglycerides, total-, low-density lipoprotein (LDL)-, and high-density lipoprotein (HDL)-cholesterol on the results, but confirmed a strong influence of plant sterols. These findings support the hypothesis that plant sterols might be an additional risk factor for CHD.

    Topics: Aged; Cholesterol; Coronary Disease; Family; Female; Humans; Male; Medical Records; Middle Aged; Osmolar Concentration; Phytosterols; Risk Factors; Sitosterols

2002
Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients.
    Atherosclerosis, 2002, Volume: 160, Issue:2

    Baseline cholesterol metabolism was hypothesized to regulate responses of cholesterol synthesis and absorption, and serum cholesterol lowering to hypolipidaemic treatment. Thus, serum cholesterol and non-cholesterol sterols were measured before and during long-term simvastatin treatment (inhibition of cholesterol synthesis) and subsequent combination of statin with plant stanol ester margarine (inhibition of cholesterol absorption) consumption in subjects with low (n=15) and high (n=15) absorption of cholesterol, defined by respective low and high baseline ratios of serum cholestanol to cholesterol. Cholesterol synthesis (defined by precursors of cholesterol) was markedly reduced by the long-term statin treatment in both groups, but more extensively in the low than high absorption group (P<0.05), yet the respective serum cholesterol reductions were similar. From among the absorption markers, sitosterol and cholestanol ratios were correspondingly increased more in the low than in the high absorption group. Plant stanol ester margarine consumption, combined with chronic statin treatment, further lowered the serum cholesterol level (P<0.001) only in the high absorption group. The sum of cholesterol absorption markers was reduced more (P<0.05) in the high than in the low absorption group, while the non-significant serum cholesterol reduction of the low absorption group was associated with relatively high increase of cholesterol synthesis. Thus, stanol ester margarine combined with chronic simvastatin treatment reduces cholesterol absorption and serum cholesterol more consistently in subjects with high than low baseline absorption of cholesterol. The profile of baseline cholesterol metabolism determines the changes in synthesis and absorption of cholesterol to hypolipidaemic treatments, but affects less differently serum cholesterol level.

    Topics: Aged; Cholestanol; Cholesterol; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Intestinal Absorption; Male; Margarine; Simvastatin; Sitosterols; Sterols

2002
Making the most of cholesterol-lowering margarines.
    Cleveland Clinic journal of medicine, 2001, Volume: 68, Issue:3

    Used as a substitute for normal dietary intake of saturated fatty acids, margarines containing plant sterols can cause a modest reduction in serum total cholesterol and low-density lipoprotein cholesterol levels. They have been shown effective in patients with mild hypercholesterolemia, but they are also useful in the general population.

    Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Costs and Cost Analysis; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Margarine; Phytosterols; Randomized Controlled Trials as Topic; Simvastatin; Sitosterols; Time Factors

2001
Food labeling: health claims; plant sterol/stanol esters and coronary heart disease. Interim final rule; notice of extension of period for issuance of final rule.
    Federal register, 2001, Jun-06, Volume: 66, Issue:109

    The Food and Drug Administration (FDA) is extending to July 25, 2001, the period for issuance of a final rule in response to its interim final rule of September 8, 2000, entitled " Food Labeling: Health Claims; Plant Sterol/Stanol Esters and Coronary Heart Disease." FDA's regulations require the agency to issue a notice of such extension if it finds, for cause, that it is unable to issue a final rule within 270 days from the date of publication of the interim final rule. The complexity of the issues raised by the comments to the interim final rule and the lack of agency resources to complete the final rule within the specified 270 days have persuaded the agency of the need to extend the deadline to publish the final rule.

    Topics: Coronary Disease; Food Labeling; Humans; Sitosterols; Time Factors; United States; United States Food and Drug Administration

2001
Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women.
    Journal of the American College of Cardiology, 2000, Volume: 35, Issue:5

    The purpose of the study was to investigate whether cholesterol metabolism is associated with coronary artery disease (CAD) in postmenopausal women.. Although hypercholesterolemia, a predominant risk factor of CAD, is related to cholesterol metabolism, the association between cholesterol metabolism and CAD is not well known.. In addition to conventional coronary risk factors, fasting serum squalene, delta8-cholestenol, desmosterol, lathosterol (indicators of cholesterol synthesis), cholestanol, campesterol and sitosterol (indicators of cholesterol absorption) were measured in 48 50- to 55-year-old consecutive women with angiographically verified CAD and in 61 age-matched healthy controls.. The coronary patients had elevated ratios of squalene (p < 0.001), desmosterol (p = 0.005), campesterol (p = 0.028) and sitosterol (p = 0.022) to cholesterol, but had lower respective lathosterol value (p = 0.041) compared with the controls, despite similar serum cholesterol levels. Adjusted for age, body mass index, family history of CAD, smoking, hypertension, serum triglycerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol level and glycosylated hemoglobin A1c% (GHbA1c), the ratios of squalene (odds ratio, 1.36; 95% confidence interval, 1.17 to 1.57), lathosterol (0.98; 0.97 to 0.99), campesterol (1.01; 1.00 to 1.01) and sitosterol (1.01; 1.00 to 1.03) were significantly associated with the risk of CAD. In addition, family history of CAD and GHbA1c% were also independently related to the presence of CAD.. The results suggest that women with elevated ratios of serum squalene, campesterol and sitosterol to cholesterol and low respective lathosterol values have enhanced risk for CAD. Thus, enhanced absorption and reduced synthesis of cholesterol may be related to coronary atherosclerosis.

    Topics: Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Desmosterol; Fasting; Female; Glycated Hemoglobin; Humans; Middle Aged; Phytosterols; Postmenopause; Prevalence; Radiography; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Sitosterols; Squalene

2000
Coronary bypass grafts in a young girl with sitosterolemia.
    European heart journal, 1996, Volume: 17, Issue:6

    Topics: Adolescent; Age of Onset; Coronary Artery Bypass; Coronary Disease; Echocardiography; Female; Humans; Lipid Metabolism, Inborn Errors; Lipoproteins; Sitosterols

1996
Lowering cholesterol with drugs and diet.
    The New England journal of medicine, 1995, Nov-16, Volume: 333, Issue:20

    Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Male; Pravastatin; Sitosterols

1995
High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
    Journal of lipid research, 1991, Volume: 32, Issue:2

    We measured the cholestanol, cholesterol precursor (lathosterol), and plant sterol (campesterol and sitosterol) concentrations of serum and bile in 11 patients with cerebrotendinous xanthomatosis. The mean values of serum cholestanol, lathosterol, campesterol, and sitosterol were, respectively, 8.4-, 2.5-, 2.7-, and 1.4-times higher in the patients than in normal control subjects (n = 26). Cholestanol (6.7-fold) and campesterol (3.7-fold) levels in bile (n = 4) were also elevated in the patients. There was no significant difference of serum sterol levels between patients with coronary artery disease and those without it. Chenodeoxycholic acid treatment for periods ranging from 6 months to 3 years and 4 months lowered serum lathosterol (57.7% reduction) and campesterol (57.8%) levels in parallel with cholestanol (70.8%) level, but the sitosterol level (19.7%) decreased less. Thus, increased levels of cholesterol precursor (lathosterol), plant sterols (campesterol and sitosterol), and cholestanol were found in the serum and bile in cerebrotendinous xanthomatosis. Chenodeoxycholic acid treatment effectively reduced the levels of these sterols, except for sitosterol.

    Topics: Adult; Bile; Chenodeoxycholic Acid; Cholestanol; Cholesterol; Chromatography, High Pressure Liquid; Coronary Disease; Female; Humans; Male; Middle Aged; Phytosterols; Sitosterols; Xanthomatosis

1991
A unique patient with coexisting cerebrotendinous xanthomatosis and beta-sitosterolemia.
    The American journal of medicine, 1981, Volume: 71, Issue:2

    An adult Chinese man presented with tendinous and tuberous xanthomatosis and severe atheromatous changes in the coronary arteries. In addition, he had chronic hemolytic anemia, with spherostomatocytic erythrocytes. Cerebrotendinous xanthomatosis was diagnosed on the basis of increased cholestanol levels in his plasma, red cells and xanthoma, changes in bile acid composition due to the defective synthesis of chenodeoxycholic acid. Coexisting beta-sitosterolemia was confirmed by the finding of large amounts of the plant sterols such as beta-sitosterol and campesterol. This is the first report of these two rare lipid storage disorders in the same patient.

    Topics: Adult; Anemia, Hemolytic; Chenodeoxycholic Acid; Cholestanols; Cholesterol; Coronary Disease; Humans; Lipidoses; Phytosterols; Sitosterols; Spherocytes; Xanthomatosis

1981
A pathophysiologic approach to managing hyperlipemia.
    American family physician, 1976, Volume: 14, Issue:2

    Hyperlipemia is one of several risk factors for premature ischemic vascular disease. It usually represents a primary, lifelong metabolic disorder and control requires changes in life-style. These include a modification of diet (commonly caloric, cholesterol and saturated fat restriction), elimination of smoking and hypertension and, frequently, drug therapy. Drugs can attack endogenous triglyceride overproduction, lipoprotein lipase deficiency or defective remnant uptake, and can decrease cholesterol production and accelerate cholesterol degradation.

    Topics: Adult; Cholestyramine Resin; Clofibrate; Coronary Disease; Female; Humans; Hyperlipidemias; Lipid Metabolism; Lipoprotein Lipase; Liver; Male; Middle Aged; Nicotinic Acids; Sitosterols; Thyroxine; Triglycerides

1976
[The importance of determining the type of hyperlipidemia for lipotropic therapy of atherosclerosis].
    Kardiologiia, 1973, Volume: 13, Issue:3

    Topics: Adult; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Electrophoresis, Polyacrylamide Gel; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipid Mobilization; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Phospholipids; Sitosterols; Triglycerides

1973
[Effect of beta-sitosterol on the blood lipid level in patients with coronary atherosclerosis].
    Terapevticheskii arkhiv, 1961, Volume: 33

    Topics: Cardiotonic Agents; Coronary Artery Disease; Coronary Disease; Humans; Lipids; Sitosterols; Sterols

1961
The effect of sitosterol on radioactive fat absorption patterns.
    The American journal of cardiology, 1959, Volume: 4

    Topics: Biological Transport; Coronary Disease; Fats; Heart; Humans; Metabolic Diseases; Sitosterols; Sterols

1959
Effect of sitosterol on the concentration of serum lipids in patients with coronary atherosclerosis.
    Circulation, 1957, Volume: 16, Issue:5

    Topics: Coronary Artery Disease; Coronary Disease; Heart; Humans; Lipids; Sitosterols; Steroids

1957